IL94228A - A method for isolating and purifying transpirin receptor proteins from bacteria and vaccines containing them - Google Patents

A method for isolating and purifying transpirin receptor proteins from bacteria and vaccines containing them

Info

Publication number: IL94228A
Authority: IL; Israel
Prior art keywords: transferrin; transferrin receptor; vaccine; haemophilus; receptor
Prior art date: 1989-04-27

Application number

IL9422890A

Other languages

English (en)

Hebrew (he)

Other versions

IL94228A0 (en

Original Assignee

Univ Technologies Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-27

Filing date

1990-04-27

Publication date

2001-03-19

1990-04-27 Application filed by Univ Technologies Int filed Critical Univ Technologies Int

1991-01-31 Publication of IL94228A0 publication Critical patent/IL94228A0/xx

2001-03-19 Publication of IL94228A publication Critical patent/IL94228A/en

2001-08-19 Priority to IL14497301A priority Critical patent/IL144973A0/xx

Links

108010033576 Transferrin Receptors Proteins 0.000 title claims abstract description 69
229960005486 vaccine Drugs 0.000 title claims abstract description 50
238000000034 method Methods 0.000 title claims abstract description 41
102000007238 Transferrin Receptors Human genes 0.000 title claims description 65
241000894006 Bacteria Species 0.000 title description 13
102000004338 Transferrin Human genes 0.000 claims abstract description 55
239000012581 transferrin Substances 0.000 claims abstract description 55
108020003175 receptors Proteins 0.000 claims abstract description 34
102000005962 receptors Human genes 0.000 claims abstract description 32
244000052616 bacterial pathogen Species 0.000 claims abstract description 27
238000002360 preparation method Methods 0.000 claims abstract description 27
238000001042 affinity chromatography Methods 0.000 claims abstract description 8
102000004169 proteins and genes Human genes 0.000 claims description 59
108090000623 proteins and genes Proteins 0.000 claims description 59
108090000901 Transferrin Proteins 0.000 claims description 48
230000027455 binding Effects 0.000 claims description 42
239000012528 membrane Substances 0.000 claims description 37
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 33
241000588650 Neisseria meningitidis Species 0.000 claims description 27
239000000872 buffer Substances 0.000 claims description 26
239000011780 sodium chloride Substances 0.000 claims description 17
230000036039 immunity Effects 0.000 claims description 15
241000588652 Neisseria gonorrhoeae Species 0.000 claims description 13
241000606790 Haemophilus Species 0.000 claims description 12
241000606768 Haemophilus influenzae Species 0.000 claims description 12
230000001580 bacterial effect Effects 0.000 claims description 12
229940047650 haemophilus influenzae Drugs 0.000 claims description 12
230000001681 protective effect Effects 0.000 claims description 12
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 11
241000606767 Avibacterium paragallinarum Species 0.000 claims description 10
241000606831 Histophilus somni Species 0.000 claims description 8
241001293418 Mannheimia haemolytica Species 0.000 claims description 8
241000588655 Moraxella catarrhalis Species 0.000 claims description 8
108010051423 streptavidin-agarose Proteins 0.000 claims description 8
241000606750 Actinobacillus Species 0.000 claims description 7
241000606856 Pasteurella multocida Species 0.000 claims description 7
229940051027 pasteurella multocida Drugs 0.000 claims description 7
239000003599 detergent Substances 0.000 claims description 6
241000606560 Avibacterium avium Species 0.000 claims description 5
241000588649 Neisseria lactamica Species 0.000 claims description 5
241000606731 Actinobacillus suis Species 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims description 3
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000001488 sodium phosphate Substances 0.000 claims description 3
229910000162 sodium phosphate Inorganic materials 0.000 claims description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims 3
230000003100 immobilizing effect Effects 0.000 claims 2
230000003381 solubilizing effect Effects 0.000 claims 2
230000007928 solubilization Effects 0.000 claims 1
238000005063 solubilization Methods 0.000 claims 1
108010071397 lactoferrin receptors Proteins 0.000 abstract description 18
239000000427 antigen Substances 0.000 abstract description 14
102000036639 antigens Human genes 0.000 abstract description 14
108091007433 antigens Proteins 0.000 abstract description 14
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 95
102000010445 Lactoferrin Human genes 0.000 description 53
235000018102 proteins Nutrition 0.000 description 53
229940078795 lactoferrin Drugs 0.000 description 48
229910052742 iron Inorganic materials 0.000 description 47
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 47
235000021242 lactoferrin Nutrition 0.000 description 46
108010063045 Lactoferrin Proteins 0.000 description 42
210000004027 cell Anatomy 0.000 description 22
101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 20
102000050459 human LTF Human genes 0.000 description 19
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 19
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 17
101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 17
239000000203 mixture Substances 0.000 description 15
208000015181 infectious disease Diseases 0.000 description 14
241000894007 species Species 0.000 description 14
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
238000005119 centrifugation Methods 0.000 description 11
239000011347 resin Substances 0.000 description 11
229920005989 resin Polymers 0.000 description 11
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 11
238000005406 washing Methods 0.000 description 11
229940016590 sarkosyl Drugs 0.000 description 10
108700004121 sarkosyl Proteins 0.000 description 10
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
244000052769 pathogen Species 0.000 description 8
241000283690 Bos taurus Species 0.000 description 7
102000002070 Transferrins Human genes 0.000 description 7
108010015865 Transferrins Proteins 0.000 description 7
238000007792 addition Methods 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
102000014914 Carrier Proteins Human genes 0.000 description 6
108091008324 binding proteins Proteins 0.000 description 6
230000002950 deficient Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
238000002955 isolation Methods 0.000 description 6
239000008188 pellet Substances 0.000 description 6
102000001554 Hemoglobins Human genes 0.000 description 5
108010054147 Hemoglobins Proteins 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
229960000789 guanidine hydrochloride Drugs 0.000 description 5
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
244000144977 poultry Species 0.000 description 5
230000001105 regulatory effect Effects 0.000 description 5
108010001336 Horseradish Peroxidase Proteins 0.000 description 4
241000606860 Pasteurella Species 0.000 description 4
102000010912 Transferrin-Binding Proteins Human genes 0.000 description 4
238000009835 boiling Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000000108 ultra-filtration Methods 0.000 description 4
241000271566 Aves Species 0.000 description 3
101000766308 Bos taurus Serotransferrin Proteins 0.000 description 3
101000812705 Gallus gallus Endoplasmin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000008133 Iron-Binding Proteins Human genes 0.000 description 3
108010035210 Iron-Binding Proteins Proteins 0.000 description 3
102000018697 Membrane Proteins Human genes 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
241000588653 Neisseria Species 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
238000013019 agitation Methods 0.000 description 3
108010038047 apolactoferrin Proteins 0.000 description 3
108010054176 apotransferrin Proteins 0.000 description 3
235000019219 chocolate Nutrition 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
244000052637 human pathogen Species 0.000 description 3
230000028993 immune response Effects 0.000 description 3
229940031937 polysaccharide vaccine Drugs 0.000 description 3
239000000523 sample Substances 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
UVGHPGOONBRLCX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoylamino]hexanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-UHFFFAOYSA-N 0.000 description 2
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000287828 Gallus gallus Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010018612 Gonorrhoea Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
208000034762 Meningococcal Infections Diseases 0.000 description 2
101710116435 Outer membrane protein Proteins 0.000 description 2
208000008939 Pneumonic Pasteurellosis Diseases 0.000 description 2
239000000589 Siderophore Substances 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
241000282887 Suidae Species 0.000 description 2
239000008272 agar Substances 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
229940072440 bovine lactoferrin Drugs 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
231100000676 disease causative agent Toxicity 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
208000001786 gonorrhea Diseases 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000006054 immunological memory Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000009424 thromboembolic effect Effects 0.000 description 2
XGYCHIPEPHYUIH-UHFFFAOYSA-N 2-mdp Chemical compound C=1C=CC=CC=1C(O)(C(CN)C)C1=CC=CC=C1 XGYCHIPEPHYUIH-UHFFFAOYSA-N 0.000 description 1
101710191936 70 kDa protein Proteins 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
101710162398 Lactoferrin-binding protein A Proteins 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010027202 Meningitis bacterial Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241000588656 Neisseriaceae Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
108010062476 Transferrin-Binding Proteins Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
201000009904 bacterial meningitis Diseases 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007330 chocolate agar Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
208000001606 epiglottitis Diseases 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011544 gradient gel Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
208000037941 meningococcal disease Diseases 0.000 description 1
201000011475 meningoencephalitis Diseases 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
201000006509 pleuropneumonia Diseases 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
230000037351 starvation Effects 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
238000011282 treatment Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL9422890A 1989-04-27 1990-04-27 A method for isolating and purifying transpirin receptor proteins from bacteria and vaccines containing them IL94228A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
IL14497301A IL144973A0 (en)	1989-04-27	2001-08-19	A vaccine which provides protective immunity against a bacterial pathogen

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34435689A	1989-04-27	1989-04-27
US07/507,481 US5292869A (en)	1989-04-27	1990-04-09	Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same

Publications (2)

Publication Number	Publication Date
IL94228A0 IL94228A0 (en)	1991-01-31
IL94228A true IL94228A (en)	2001-03-19

Family

ID=26993881

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL9422890A IL94228A (en)	1989-04-27	1990-04-27	A method for isolating and purifying transpirin receptor proteins from bacteria and vaccines containing them
IL14497301A IL144973A0 (en)	1989-04-27	2001-08-19	A vaccine which provides protective immunity against a bacterial pathogen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL14497301A IL144973A0 (en)	1989-04-27	2001-08-19	A vaccine which provides protective immunity against a bacterial pathogen

Country Status (12)

Country	Link
US (1)	US5292869A (fr)
EP (1)	EP0528787B1 (fr)
KR (1)	KR100240974B1 (fr)
AT (1)	ATE173935T1 (fr)
AU (1)	AU649950B2 (fr)
CA (1)	CA2051808C (fr)
DE (1)	DE69032806T2 (fr)
DK (1)	DK0528787T3 (fr)
ES (1)	ES2127184T3 (fr)
IL (2)	IL94228A (fr)
NZ (2)	NZ233471A (fr)
WO (1)	WO1990012591A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2329979T3 (es) *	1990-08-23	2009-12-03	The University Of North Carolina At Chapel Hill	Proteinas de union de transferencia de neisseria gonorrhoeae y neisseria meningitis. su uso como vacuna.
FR2682114B1 (fr) *	1991-10-03	1996-02-23	Pasteur Merieux Serums Vacc	Vaccin de sous-unite contre les infections a neisseria meningitidis et sous-unites correspondantes a l'etat purifie.
FR2682041B1 (fr) *	1991-10-03	1994-01-14	Pasteur Merieux Serums Vaccins	Vaccin contre les infections a neisseria meningitidis.
US5417971A (en) *	1991-10-22	1995-05-23	University Of Saskatchewan	Vaccines for Actinobacillus pleuropneumoniae
FR2692592B1 (fr) *	1992-06-19	1995-03-31	Pasteur Merieux Serums Vacc	Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
US5534256A (en) *	1992-07-02	1996-07-09	University Of Saskatchewan	Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
WO1994005783A1 (fr) *	1992-09-07	1994-03-17	Bioproperties (Australia) Pty. Limited	Nouvel organisme du genre haemophilis et vaccins le contenant
DK0749321T3 (da)	1994-02-09	2007-03-12	Epitopix Llc	Aktiv immunisering under anvendelse af et sideroforreceptorprotein
US5830479A (en) *	1994-02-09	1998-11-03	Willmar Poultry Company, Inc.	Active immunization using a siderophore receptor protein
US6121427A (en) *	1994-10-24	2000-09-19	Connaught Laboratories Limited	Major outer membrane protein CD of branhamella
US6440425B1 (en) *	1995-05-01	2002-08-27	Aventis Pasteur Limited	High molecular weight major outer membrane protein of moraxella
US5817789A (en)	1995-06-06	1998-10-06	Transkaryotic Therapies, Inc.	Chimeric proteins for use in transport of a selected substance into cells
US6290970B1 (en)	1995-10-11	2001-09-18	Aventis Pasteur Limited	Transferrin receptor protein of Moraxella
US6048539A (en) *	1995-11-02	2000-04-11	Connaught Laboratories Limited	Lactoferrin receptor protein
US6610506B1 (en)	1995-12-01	2003-08-26	University Technologies International, Inc.	Transferrin binding proteins of Pasteurella haemolytica and vaccines containing same
JP2000502249A (ja) *	1995-12-01	2000-02-29	ロウ、レジー・ワイ・シー	パスツレラ・ヘモリチカのトランスフェリン結合タンパク質およびそれを含有するワクチン
US6090576A (en) *	1996-03-08	2000-07-18	Connaught Laboratories Limited	DNA encoding a transferrin receptor of Moraxella
US6440701B1 (en)	1996-03-08	2002-08-27	Aventis Pasteur Limited	Transferrin receptor genes of Moraxella
ES2271987T3 (es) *	1997-01-31	2007-04-16	Wyeth Holdings Corporation	Proteina de 74 kilodalton de la membrana externa de moraxella catarrhalis.
US5977337A (en)	1997-06-03	1999-11-02	Connaught Laboratories Limited	Lactoferrin receptor genes of Moraxella
AU739129B2 (en) *	1997-06-03	2001-10-04	Connaught Laboratories Limited	Lactoferrin receptor genes of moraxella
FR2767060B1 (fr) *	1997-08-07	2000-02-11	Pasteur Merieux Serums Vacc	Vaccin meningocoque comportant la valence de souche bz83
GB9810084D0 (en)	1998-05-11	1998-07-08	Cortecs Uk Ltd	Proteins
FR2785293B1 (fr)	1998-10-30	2002-07-05	Pasteur Merieux Serums Vacc	Acides nucleiques et polypeptides specifiques des souches pathogenes du genre neisseria
GB9823978D0 (en) *	1998-11-02	1998-12-30	Microbiological Res Authority	Multicomponent meningococcal vaccine
US10967045B2 (en)	1998-11-02	2021-04-06	Secretary of State for Health and Social Care	Multicomponent meningococcal vaccine
US6391316B1 (en) *	1999-03-10	2002-05-21	University Of Saskatchewan	Vaccine compositions comprising Haemophilus somnus transferrin-binding proteins and methods of use
US7241449B1 (en)	1999-04-12	2007-07-10	Aventis Pasteur Limited	Transferrin receptor genes of moraxella
US6682754B2 (en)	1999-11-24	2004-01-27	Willmar Poultry Company, Inc.	Ovo delivery of an immunogen containing implant
MXPA03006038A (es) *	2001-01-03	2005-02-14	Willmar Poultry Co Inc	Composiciones inmunizantes y metodos de uso.
US8129504B2 (en) *	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
US7759055B2 (en) *	2002-08-28	2010-07-20	Millipore Corporation	Compositions of solution for sequencing reaction clean-up
AU2004274977B2 (en)	2003-09-19	2011-06-23	Epitopix, Llc	Campylobacter polypeptides and methods of use
US8007811B2 (en)	2005-02-14	2011-08-30	Epitopix, Llc	Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
BRPI1011856A2 (pt)	2009-03-23	2020-11-03	Epitopix, Llc	polipeptídeos e composições de imunização contendo polipeptídeos gram-positivos e métodos de uso
CA2818173C (fr)	2010-11-30	2022-05-03	Genentech, Inc.	Anticorps anti-recepteur de la barriere hemato-encephalique a faible affinite et leurs utilisations
ES2912751T3 (es)	2013-12-02	2022-05-27	Eng Antigens Inc	Composiciones inmunogénicas y vacunas derivadas de proteínas receptoras de superficie bacteriana
US10166280B2 (en)	2016-06-08	2019-01-01	Epitopix, Llc	Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2227861B1 (fr) *	1973-05-04	1976-07-02	Anvar
US4220638A (en) *	1978-10-12	1980-09-02	Merck & Co., Inc.	Antigenic complex from N. Gonorrhoeae
US4271147A (en) *	1980-01-10	1981-06-02	Behringwerke Aktiengesellschaft	Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4447547A (en) *	1980-04-09	1984-05-08	University Patents, Inc.	Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein
US4434156A (en) *	1981-10-26	1984-02-28	The Salk Institute For Biological Studies	Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4681761A (en) *	1985-10-24	1987-07-21	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine
AU626288B2 (en) *	1988-02-05	1992-07-30	Commonwealth Scientific And Industrial Research Organisation	Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence
FR2644346B1 (fr) *	1989-03-20	1994-05-13	Rhone Merieux	Vaccins contre les bacteries septicemiques, preparations d'antigenes de bacteries septicemiques, nouvelles bacteries et vecteurs pour la preparation de ces antigenes ou vaccins

1990
- 1990-04-09 US US07/507,481 patent/US5292869A/en not_active Expired - Fee Related
- 1990-04-26 WO PCT/CA1990/000131 patent/WO1990012591A1/fr not_active Ceased
- 1990-04-26 EP EP90906093A patent/EP0528787B1/fr not_active Expired - Lifetime
- 1990-04-26 AT AT90906093T patent/ATE173935T1/de not_active IP Right Cessation
- 1990-04-26 CA CA002051808A patent/CA2051808C/fr not_active Expired - Fee Related
- 1990-04-26 DK DK90906093T patent/DK0528787T3/da active
- 1990-04-26 AU AU55261/90A patent/AU649950B2/en not_active Ceased
- 1990-04-26 ES ES90906093T patent/ES2127184T3/es not_active Expired - Lifetime
- 1990-04-26 KR KR1019910701442A patent/KR100240974B1/ko not_active Expired - Fee Related
- 1990-04-26 DE DE69032806T patent/DE69032806T2/de not_active Expired - Fee Related
- 1990-04-27 NZ NZ233471A patent/NZ233471A/en unknown
- 1990-04-27 IL IL9422890A patent/IL94228A/en not_active IP Right Cessation
- 1990-04-27 NZ NZ247967A patent/NZ247967A/en unknown
2001
- 2001-08-19 IL IL14497301A patent/IL144973A0/xx unknown

Also Published As

Publication number	Publication date
KR100240974B1 (ko)	2000-08-01
AU5526190A (en)	1990-11-16
DE69032806D1 (de)	1999-01-14
US5292869A (en)	1994-03-08
CA2051808C (fr)	1999-12-14
DK0528787T3 (da)	1999-08-16
ES2127184T3 (es)	1999-04-16
ATE173935T1 (de)	1998-12-15
EP0528787A1 (fr)	1993-03-03
CA2051808A1 (fr)	1990-10-28
NZ247967A (en)	1995-02-24
NZ233471A (en)	1993-11-25
KR920700688A (ko)	1992-08-10
IL144973A0 (en)	2002-06-30
WO1990012591A1 (fr)	1990-11-01
IL94228A0 (en)	1991-01-31
AU649950B2 (en)	1994-06-09
EP0528787B1 (fr)	1998-12-02
DE69032806T2 (de)	1999-08-05

Legal Events

Date	Code	Title
2001-07-24	FF	Patent granted
2002-02-10	KB20	Patent renewed for 20 years
2011-04-28	EXP	Patent expired

Publication	Publication Date	Title
EP0528787B1 (fr)	1998-12-02	Procede permettant d'isoler et de purifier des proteines receptrices de transferrine et de lactoferrine a partir de bacteries et preparation de vaccins contenant de telles proteines
US5141743A (en)	1992-08-25	Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
KR100242179B1 (ko)	2000-08-01	디스크 드라이브 데이타경로 보전 제어구조
US6177085B1 (en)	2001-01-23	Generation of immune response using immunogenic conjugate of molecules
Danve et al.	1993	Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals
Frasch et al.	1978	Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
Gilleland Jr et al.	1984	Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice
Munson et al.	1983	Purification and comparison of outer membrane protein P2 from Haemophilus influenzae type b isolates.
Une et al.	1984	Roles of V antigen in promoting virulence and immunity in yersiniae.
Verstreate et al.	1982	Outer membrane proteins of Brucella abortus: isolation and characterization
US6558677B2 (en)	2003-05-06	Vaccine against gram negative bacteria
Cryz Jr et al.	1983	Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide
CN100387618C (zh)	2008-05-14	无细胞百日咳疫苗和其制备方法
Banerjee-Bhatnagar et al.	1990	Expression of Neisseria meningitidis iron-regulated outer membrane proteins, including a 70-kilodalton transferrin receptor, and their potential for use as vaccines
Frasch	1977	Role of protein serotype antigens in protection against disease due to Neisseria meningitidis
JP2004189751A (ja)	2004-07-08	非細胞性（Ａｃｅｌｌｕｌａｒ）百日咳ワクチン及びその調製方法
Craven et al.	1979	Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model
CA1251396A (fr)	1989-03-21	Vaccins contenant des proteines ou des complexes peptidiques immunogenes
IL127163A (en)	2002-11-10	Vaccine which provides protective immunity against a bacterial pathogen
JP3335622B2 (ja)	2002-10-21	細菌からトランスフェリン及びラクトフェリン受容体タンパク質を分離及び精製する方法並びにこれらを含有するワクチンを調製する方法
Beachey	1986	Type-specific opsonic antibodies evoked with a synthetic peptide of streptococcal M protein conjugated to polylysine without adjuvant
CN104096224B (zh)	2020-06-19	一种增强流行性嗜血杆菌b型多糖蛋白结合物免疫原性的方法
AU662116B2 (en)	1995-08-24	Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
LOEB et al.	1989	Evaluating vaccine candidates for the prevention of otitis media
Green et al.	1991	Overview: Bacterial Lipoproteins as Vaccines Candidates and Patent Considerations